GLTO Galecto Inc.

Biotech Analyst Ratings

Latest News

1. 02 May 2022 Galecto to Participate at Upcoming Investor Conferences

   BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-on-one meetings at the following upcoming conferences:
   

   BofA Securities 2022 Healthcare Conference
   Date:	Tuesday, May 10
   Time:	3:40 pm ET / 12:40 pm PT
   Presentation:	Click Here
   A replay of the presentation will be available on the investors portion of the company's website.
   H.C. Wainwright Global Investment Conference
   Date:	May 23-26
   Time:	On demand presentation
   Register:	Click Here

   About Galecto
   Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors…

   View Full Article
2. 29 April 2022 Galecto Reports First Quarter Operating and Financial Results

   BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter ended March 31, 2022.
   

   "We continued to execute this quarter, and importantly completed enrollment in two of our three ongoing Phase 2 trials: GALACTIC-1 in IPF and GULLIVER-2 in liver cirrhosis," said Hans Schambye, CEO of Galecto. "As we await topline data from GULLIVER-2 later this year, we look forward to other important milestones, including initiating enrollment in GALLANT-1, our Phase 2 trial in first-line NSCLC, and completing enrollment in MYLOX-1, our Phase 2 trial in myelofibrosis…

   View Full Article
3. 26 April 2022 Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

   GB0139 is Galecto's proprietary inhaled once-daily small molecule galectin-3 inhibitor
   

   GALACTIC-1 trial on track to deliver top-line results in mid-2023

   BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment of patients in its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis (IPF).

   IPF is a life-threatening, rapidly progressing and irreversible disease causing scarring of the lungs and significantly impairing lung function. IPF affects approximately 100,000 people in the United States and is associated with significant morbidity and mortality…

   View Full Article
4. 29 March 2022 Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

   Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
   

   Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021

   BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part Phase 1b/2a trial of GB1211, GULLIVER-2, in liver cirrhosis.

   GB1211 is a selective, oral small molecule inhibitor of galectin-3 being studied in liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and for which there are limited treatment options. GULLIVER-2 is an innovative…

   View Full Article
5. 17 February 2022 Galecto Reports Financial Results for the Year Ended December 31, 2021

   Continued pipeline progress with three potentially first-in-class product candidates
   

   Strong cash position with cash runway into 2H 2024

   BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31, 2021.

   "During 2021, we made significant progress with our pipeline as we advanced two additional product candidates, GB2064 for myelofibrosis and GB1211 for liver cirrhosis, to Phase 2 clinical testing. With these trials and our ongoing Phase 2b GALACTIC-1 trial for idiopathic pulmonary fibrosis (IPF), we now have three separate ongoing Phase…

   View Full Article